A PK and Salvage Study for Children With HIV-infection

Lopinavir/r Plus Saquinavir Salvage Therapy in HIV-infected Children With NRTI and/or NNRTI Failure: PK and Two-year Treatment Follow up

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00476359

Enrollment

Registered

2007-05-22

Start date

2003-10-31

Completion date

2008-11-30

Last updated

2015-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections

Keywords

Lopinavir/r, Saquinavir, Dual boosted PIs, Pharmacokinetics, HIV children, C min, Second line HAART, ARV, VL failure, Dosage, To evaluate treatment response, Treatment Experienced

Brief summary

To evaluate the pharmacokinetics (PK) of LPV/r with saquinavir in HIV-1 infected children. To evaluate treatment response (clinical, immunological and virological) to LPV/r, SQV in Thai children.

Detailed description

The PK and 24 week data has been published in Pediatric Infectious Diseases Journal. It showed that plasma drug concentrations of saquinavir, lopinavir and ritonavir were at the higher limits of expected ranges for adult treatment at approved dosages (1000/100 mg BID for saquinavir, 400/100 mg BID for lopinavir/r). The regimen was well tolerated and showed significant CD4 rise and VL decline at 48 weeks.

Interventions

DRUGLopinavir/r plus saquinavir

lopinavir/ritonavir 230/57.5 mg/m2 orally twice daily and saquinavir 50 mg/kg orally twice daily

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

1 Years to 16 Years

Healthy volunteers

Inclusion criteria

1. Confirmed HIV-1 infection by HIV-DNA PCR if \< 18 months old or by HIV ELISA if greater than or equal to 18 months old 2. Subject is less than or equal to 16 years of age at the day of the first dosing. 3. Subject is failing a current NRTI and/or NNRTI containing regimen and is naïve to protease inhibitor containing therapy. 4. Results of biochemistry and haematology testing should be within pre-specified ranges. 5. Subject is able to swallow capsules 6. Caretaker(s) is/are able and willing to sign the Informed Consent Form prior to screening evaluations.

Exclusion criteria

1. History of sensitivity/idiosyncrasy to lopinavir, ritonavir, saquinavir or chemically related compounds or excipients which may be employed in the trial. 2. Relevant history or current condition that might interfere with drug absorption, distribution, metabolism or excretion. 3. Inability of both child and caregiver(s) to understand the nature and extent of the trial and the procedures required. 4. Use of any of concomitant medication, including the drug listed below, that may interfere with the pharmacokinetics of LPV/r or SQV. * NNRTIs * Rifampicin * Rifabutin * Phenobarbital * Phenytoine * Carbamazepine * Dexamethasone * Ketoconazole * Clarithromycin 5. Pregnancy

Design outcomes

Primary

Measure	Time frame
Intensive 0-12h PK sampling for plasma levels of LPV and SQV, and blood sampling. CD4 viral load safety lab every 3 months.	96 week

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026